Psoriatic Disease News

In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a study published in JAMA Dermatology.

Patients treated with interleukin-23i or IL-12/23i for psoriasis exhibited similar rates of risk for developing psoriatic arthritis, according to a study.

The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.

Poor representation of darker skin tones in dermatology training materials has led to delayed diagnoses and worse treatment outcomes in Black, Asian and non-white Latin American patients, according to a presenter.

Healio has compiled July’s most-read news in dermatology.

Patients with psoriasis, specifically those with a high BMI, had lower concentrations of polyunsaturated fatty acids and elevated concentrations of saturated fatty acid, which correlate to greater disease severity, according to a study.

Guselkumab for psoriatic arthritis led to major improvements in joint disease activity, complete skin clearance and other “stringent” endpoints that were maintained through 2 years, according to data published in Clinical Rheumatology.

Healio has compiled June’s most-read news in dermatology.

Makeup not only has cosmetic applications, but medical ones too.

The FDA has approved the Stelara biosimilar Pyzchiva for psoriatic arthritis, Crohn’s disease and all other indications approved for the reference medicine, according to a press release from Sandoz.